Department of Radiation Oncology, University Medical Center Utrecht, the Netherlands.
Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Austria.
Radiother Oncol. 2019 May;134:185-190. doi: 10.1016/j.radonc.2019.02.007. Epub 2019 Feb 26.
PURPOSE/OBJECTIVE(S): To investigate the patterns of nodal failure in patients enrolled in the international multicentre EMBRACE study.
MATERIALS/METHODS: Nodal disease at diagnosis (N-, N+) and nodal failure were analysed per region (NF) (pelvic (parametrial, common iliac, internal/external iliac), inguinal and para-aortic (PAO)) in 1338 patients. Treatment consisted of chemo-radiation and MRI guided brachytherapy. PAO radiotherapy and/or nodal boost was left to the treating centre. At time of diagnosis 52% of patients had pathologic nodes. Frequency analyses were performed in relation to patient, primary tumour and nodal disease characteristics, and treatment related factors.
Median follow up was 34 months and 83% of NF occurred within 24 months. At diagnosis 99% of the N+ patients had pathologic nodes in the pelvis and 14% in the PAO. NF and NF were reported in 55% and 68% of patients with NF, respectively. Overall NF was reported in 152 patients (11%); 7 and 16% for N- and N+ patients. Of the patients with NF, 41% were located outside the elective target (39% PAO), 40% inside and 35% inside the nodal boost target. Twelve percent of N+ patients that received a nodal boost had a NF inside the nodal boost target.
Within the EMBRACE study cohort the overall number of patients developing nodal failure is low, significantly lower for N- compared to N+ patients. Pathological nodes at diagnosis are mainly located in the pelvis, whereas nodal failures are more often reported in the PAO region. About 40% of all nodal failures were reported outside the treatment targets.
研究国际多中心 EMBRACE 研究中入组患者的淋巴结失败模式。
对 1338 例患者的区域淋巴结疾病(N-、N+)和淋巴结失败(NF)(盆腔(宫旁、髂总、内/外髂)、腹股沟和腹主动脉旁(PAO))进行分析。治疗包括放化疗和 MRI 引导下近距离放疗。PAO 放疗和/或淋巴结加量放疗由治疗中心决定。诊断时,52%的患者有病理淋巴结。与患者、原发肿瘤和淋巴结疾病特征以及治疗相关因素相关的频率分析。
中位随访时间为 34 个月,83%的 NF 在 24 个月内发生。诊断时,99%的 N+患者的盆腔有病理淋巴结,14%的患者的 PAO 有病理淋巴结。NF 和 NF 分别在 55%和 68%的 NF 患者中报告。共有 152 例(11%)患者发生总体 NF,N-和 N+患者分别为 7%和 16%。在发生 NF 的患者中,41%位于选择性靶区外(39%在 PAO 区),40%位于靶区内,35%位于淋巴结加量靶区内。接受淋巴结加量放疗的 N+患者中有 12%出现淋巴结加量靶区内的 NF。
在 EMBRACE 研究队列中,发生淋巴结失败的患者总数较低,N-患者明显低于 N+患者。诊断时的病理淋巴结主要位于盆腔,而淋巴结失败更多见于 PAO 区。约 40%的所有淋巴结失败发生在治疗靶区外。